Nanox grew its Q3 revenue year-over-year to $3.4M, but continued to operate at a net loss as it invested in commercialization and AI development. The acquisition of Vaso Healthcare IT and expanding clinical trials marked key strategic steps.

In Q2 2025, Nano-X reported $3.04 million in revenue, a modest increase driven by growth in its teleradiology segment. However, the company reported a net loss of $14.7 million and a gross loss margin of 37.2%, as it continues investing in commercialization efforts for its imaging systems and AI platforms. Cash reserves decreased to $58.3 million, and the company reaffirmed its focus on product deployment and expanding imaging services.

Nanox posted a net loss of $13.2M for Q1 2025, with revenue reaching $2.8M. The company received FDA clearance for its updated ARC X system and continued expanding its commercial deployments.

Nanox generated $3.0 million in revenue for Q4 2024, up from $2.4 million in the prior year period. Despite revenue growth, the company posted a net loss of $14.1 million and an operating loss of $15.0 million. The non-GAAP EPS stood at -$0.17. Teleradiology services accounted for most of the revenue.